Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer
Conclusions:
This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Authors: Lebret, T., Rouanne, M., Hublarov, O., Jinga, V., Petkova, L., Kotsev, R., Sinescu, I., Dutailly, P. Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Erectile Dysfunction | Hormones | Prostate Cancer | Study | Urology & Nephrology